Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000406460 | SCV000342846 | uncertain significance | not provided | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001062907 | SCV001227732 | uncertain significance | Glycogen storage disease, type II | 2021-08-24 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with alanine at codon 473 of the GAA protein (p.Gly473Ala). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and alanine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with GAA-related conditions. ClinVar contains an entry for this variant (Variation ID: 288673). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001062907 | SCV002027274 | uncertain significance | Glycogen storage disease, type II | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001062907 | SCV005653203 | uncertain significance | Glycogen storage disease, type II | 2024-02-28 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001062907 | SCV002092028 | uncertain significance | Glycogen storage disease, type II | 2019-10-28 | no assertion criteria provided | clinical testing |